Introduction: The SGLT2 inhibitor empagliflozin (EMPA) exerts beneficial cardiovascular effects in type-2 diabetes, but whether this occurs in chronic heart failure (CHF) is unknown. Thus we investigated, using a rat model whether EMPA exhibits protective effect in chronic heart failure (CHF).

Methods: Rats with CHF were treated with EMPA (30 mg/kg PO for 7 days starting 83 days after coronary artery ligation or 90 days starting 7 days after coronary artery ligation) to assess effects on left ventricular (LV) function and hemodynamics (echocardiography, LV catheterization).

Results: After 90 days untreated CHF rats presented LV systolic and diastolic dysfunction, illustrated by the decreases in LV end-systolic pressure (LV ESP) and in LV end-systolic pressure volume-relation (LV ESPVR) as well as the increases in LV end-diastolic pressure (LV EDP) and LV end-diastolic pressure volume-relation (LV EDPVR). Seven- and ninety-day EMPA treatment improved systolic and diastolic LV function, illustrated by the increases in LV ESP and in LV ESPVR as well as the reductions in LV EDP and in LV EDPVR.

Conclusion: Short- and long-term EMPA treatment prevents LV dysfunction in rats with CHF. These results suggest that EMPA may exert protective effects in humans with CHF.


M. Soulié: None. Y. Stephan: None. L. Nicol: None. J. Henry: None. V. Richard: None. M. Pieper: Employee; Self; Boehringer Ingelheim Pharmaceuticals, Inc. P. Mulder: Research Support; Self; Bayer Healthcare Pharmaceuticals Inc., Boehringer Ingelheim Pharmaceuticals, Inc., Poxel SA.


Boehringer Ingelheim

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at